Join Growin Stock Community!

Genmab a/sGMAB.US Overview

US StockHealthcare
(No presentation for GMAB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GMAB AI Insights

GMAB Overall Performance

GMAB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GMAB Recent Performance

-0.70%

Genmab a/s

0.05%

Avg of Sector

-0.31%

S&P500

GMAB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GMAB Key Information

GMAB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GMAB Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Price of GMAB

GMAB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GMAB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.56
PE Ratio (TTM)
19.12
Forward PE
1.84
PS Ratio (TTM)
4.87
PB Ratio
3.08
Price-to-FCF
16.15
METRIC
VALUE
vs. INDUSTRY
Gross Margin
93.60%
Net Margin
25.89%
Revenue Growth (YoY)
23.44%
Profit Growth (YoY)
21.08%
3-Year Revenue Growth
-41.29%
3-Year Profit Growth
-42.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.56
PE Ratio (TTM)
19.12
Forward PE
1.84
PS Ratio (TTM)
4.87
PB Ratio
3.08
Price-to-FCF
16.15
Gross Margin
93.60%
Net Margin
25.89%
Revenue Growth (YoY)
23.44%
Profit Growth (YoY)
21.08%
3-Year Revenue Growth
-41.29%
3-Year Profit Growth
-42.82%

  • When is GMAB's latest earnings report released?

    The most recent financial report for Genmab a/s (GMAB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GMAB's short-term business performance and financial health. For the latest updates on GMAB's earnings releases, visit this page regularly.

  • Where does GMAB fall in the P/E River chart?

    According to historical valuation range analysis, Genmab a/s (GMAB)'s current price-to-earnings (P/E) ratio is 20.01, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of GMAB?

    According to the latest financial report, Genmab a/s (GMAB) reported an Operating Profit of 58M with an Operating Margin of 5.48% this period, representing a decline of 80.82% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GMAB's revenue growth?

    In the latest financial report, Genmab a/s (GMAB) announced revenue of 1.06B, with a Year-Over-Year growth rate of 17.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does GMAB have?

    As of the end of the reporting period, Genmab a/s (GMAB) had total debt of 5.43B, with a debt ratio of 0.42. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GMAB have?

    At the end of the period, Genmab a/s (GMAB) held Total Cash and Cash Equivalents of 1.72B, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GMAB go with three margins increasing?

    In the latest report, Genmab a/s (GMAB) achieved the “three margins increasing” benchmark, with a gross margin of 92.3%%, operating margin of 5.48%%, and net margin of 2.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GMAB's profit trajectory and future growth potential.

  • Is GMAB's EPS continuing to grow?

    According to the past four quarterly reports, Genmab a/s (GMAB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GMAB?

    Genmab a/s (GMAB)'s Free Cash Flow (FCF) for the period is 288M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of GMAB?

    The latest valuation data shows Genmab a/s (GMAB) has a Price-To-Earnings (PE) ratio of 20.01 and a Price/Earnings-To-Growth (PEG) ratio of -3.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.